HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma

Roberta Mancuso, Renato Biffi, Marilena Valli, Monica Bellinvia, Tourlaki Athanasia, Silvia Ferrucci, Lucia Brambilla, Serena Delbue, Pasquale Ferrante, Carmine Tinelli, Mario Clerici

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The link between human herpesvirus 8 (KSHV) and Kaposi's sarcoma (KS) has been proven, but many important aspects including risk factors, genetic predisposition to tumor development, transmission of KSHV, and the pathogenic potential of different genotypes remain to be elucidated. Possible associations between clinical parameters and antibody levels, viral load fluctuations, and viral genotype were analyzed by quantitative real-time PCR, an in-house developed IFA assay, and sequence analysis of ORFK1-VR1 in blood, serum and saliva of 38 subjects with classic KS (cKS). KSHV lytic antibodies were significantly increased in stage IV compared to stage I and II patients (p=0.006 and p=0.041, respectively). KSHV blood, serum, and saliva viral load was comparable in all stages. The highest viral loads were detected in saliva, and they decreased in stages III-IV compared to stages I-II patients. Higher concentrations of lytic antibodies and higher viral loads were observed in fast progressing cKS patients, in whom KSHV detection from blood was also more frequent. Type A KSHV strain was almost exclusively present in rapid progressors (12/17 cases), while C type was mainly present in slow progressing patients (6/7 cases). Finally, detection of type A KSHV strain associated with higher blood viral loads. KSHV lytic antibody levels and viral load can be used to monitor clinical evolution of cKS. Infection supported by KSHV A subtype is associated with more rapid progressive disease. Careful monitoring and aggressive therapeutic protocols should be considered in patients with KSHV A-supported infection.

Original languageEnglish
Pages (from-to)2153-2160
Number of pages8
JournalJournal of Medical Virology
Volume80
Issue number12
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Human Herpesvirus 8
Kaposi's Sarcoma
Viral Load
Saliva
Antibodies
Genotype
Genetic Predisposition to Disease
Infection
Serum
Sequence Analysis
Real-Time Polymerase Chain Reaction

Keywords

  • Classic Kaposi's sarcoma
  • HHV8
  • HHV8 subtypes
  • Tumor progression

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma. / Mancuso, Roberta; Biffi, Renato; Valli, Marilena; Bellinvia, Monica; Athanasia, Tourlaki; Ferrucci, Silvia; Brambilla, Lucia; Delbue, Serena; Ferrante, Pasquale; Tinelli, Carmine; Clerici, Mario.

In: Journal of Medical Virology, Vol. 80, No. 12, 12.2008, p. 2153-2160.

Research output: Contribution to journalArticle

Mancuso, Roberta ; Biffi, Renato ; Valli, Marilena ; Bellinvia, Monica ; Athanasia, Tourlaki ; Ferrucci, Silvia ; Brambilla, Lucia ; Delbue, Serena ; Ferrante, Pasquale ; Tinelli, Carmine ; Clerici, Mario. / HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma. In: Journal of Medical Virology. 2008 ; Vol. 80, No. 12. pp. 2153-2160.
@article{ada0a53d77e245fdbc808c9c5b8fbc5e,
title = "HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma",
abstract = "The link between human herpesvirus 8 (KSHV) and Kaposi's sarcoma (KS) has been proven, but many important aspects including risk factors, genetic predisposition to tumor development, transmission of KSHV, and the pathogenic potential of different genotypes remain to be elucidated. Possible associations between clinical parameters and antibody levels, viral load fluctuations, and viral genotype were analyzed by quantitative real-time PCR, an in-house developed IFA assay, and sequence analysis of ORFK1-VR1 in blood, serum and saliva of 38 subjects with classic KS (cKS). KSHV lytic antibodies were significantly increased in stage IV compared to stage I and II patients (p=0.006 and p=0.041, respectively). KSHV blood, serum, and saliva viral load was comparable in all stages. The highest viral loads were detected in saliva, and they decreased in stages III-IV compared to stages I-II patients. Higher concentrations of lytic antibodies and higher viral loads were observed in fast progressing cKS patients, in whom KSHV detection from blood was also more frequent. Type A KSHV strain was almost exclusively present in rapid progressors (12/17 cases), while C type was mainly present in slow progressing patients (6/7 cases). Finally, detection of type A KSHV strain associated with higher blood viral loads. KSHV lytic antibody levels and viral load can be used to monitor clinical evolution of cKS. Infection supported by KSHV A subtype is associated with more rapid progressive disease. Careful monitoring and aggressive therapeutic protocols should be considered in patients with KSHV A-supported infection.",
keywords = "Classic Kaposi's sarcoma, HHV8, HHV8 subtypes, Tumor progression",
author = "Roberta Mancuso and Renato Biffi and Marilena Valli and Monica Bellinvia and Tourlaki Athanasia and Silvia Ferrucci and Lucia Brambilla and Serena Delbue and Pasquale Ferrante and Carmine Tinelli and Mario Clerici",
year = "2008",
month = "12",
doi = "10.1002/jmv.21322",
language = "English",
volume = "80",
pages = "2153--2160",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma

AU - Mancuso, Roberta

AU - Biffi, Renato

AU - Valli, Marilena

AU - Bellinvia, Monica

AU - Athanasia, Tourlaki

AU - Ferrucci, Silvia

AU - Brambilla, Lucia

AU - Delbue, Serena

AU - Ferrante, Pasquale

AU - Tinelli, Carmine

AU - Clerici, Mario

PY - 2008/12

Y1 - 2008/12

N2 - The link between human herpesvirus 8 (KSHV) and Kaposi's sarcoma (KS) has been proven, but many important aspects including risk factors, genetic predisposition to tumor development, transmission of KSHV, and the pathogenic potential of different genotypes remain to be elucidated. Possible associations between clinical parameters and antibody levels, viral load fluctuations, and viral genotype were analyzed by quantitative real-time PCR, an in-house developed IFA assay, and sequence analysis of ORFK1-VR1 in blood, serum and saliva of 38 subjects with classic KS (cKS). KSHV lytic antibodies were significantly increased in stage IV compared to stage I and II patients (p=0.006 and p=0.041, respectively). KSHV blood, serum, and saliva viral load was comparable in all stages. The highest viral loads were detected in saliva, and they decreased in stages III-IV compared to stages I-II patients. Higher concentrations of lytic antibodies and higher viral loads were observed in fast progressing cKS patients, in whom KSHV detection from blood was also more frequent. Type A KSHV strain was almost exclusively present in rapid progressors (12/17 cases), while C type was mainly present in slow progressing patients (6/7 cases). Finally, detection of type A KSHV strain associated with higher blood viral loads. KSHV lytic antibody levels and viral load can be used to monitor clinical evolution of cKS. Infection supported by KSHV A subtype is associated with more rapid progressive disease. Careful monitoring and aggressive therapeutic protocols should be considered in patients with KSHV A-supported infection.

AB - The link between human herpesvirus 8 (KSHV) and Kaposi's sarcoma (KS) has been proven, but many important aspects including risk factors, genetic predisposition to tumor development, transmission of KSHV, and the pathogenic potential of different genotypes remain to be elucidated. Possible associations between clinical parameters and antibody levels, viral load fluctuations, and viral genotype were analyzed by quantitative real-time PCR, an in-house developed IFA assay, and sequence analysis of ORFK1-VR1 in blood, serum and saliva of 38 subjects with classic KS (cKS). KSHV lytic antibodies were significantly increased in stage IV compared to stage I and II patients (p=0.006 and p=0.041, respectively). KSHV blood, serum, and saliva viral load was comparable in all stages. The highest viral loads were detected in saliva, and they decreased in stages III-IV compared to stages I-II patients. Higher concentrations of lytic antibodies and higher viral loads were observed in fast progressing cKS patients, in whom KSHV detection from blood was also more frequent. Type A KSHV strain was almost exclusively present in rapid progressors (12/17 cases), while C type was mainly present in slow progressing patients (6/7 cases). Finally, detection of type A KSHV strain associated with higher blood viral loads. KSHV lytic antibody levels and viral load can be used to monitor clinical evolution of cKS. Infection supported by KSHV A subtype is associated with more rapid progressive disease. Careful monitoring and aggressive therapeutic protocols should be considered in patients with KSHV A-supported infection.

KW - Classic Kaposi's sarcoma

KW - HHV8

KW - HHV8 subtypes

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=57349161263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349161263&partnerID=8YFLogxK

U2 - 10.1002/jmv.21322

DO - 10.1002/jmv.21322

M3 - Article

VL - 80

SP - 2153

EP - 2160

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 12

ER -